{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:46:01Z","timestamp":1792442761117,"version":"4.5.0"},"reference-count":44,"publisher":"Walter de Gruyter GmbH","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpm-2016-0178_s_999_w2aab3b7b3b1b6b1aab1c17b1Aa\">\n                  <jats:title id=\"d1389240e6931_w2aab3b7b3b1b6b1aab1c17b1aAa\">Introduction:<\/jats:title>\n                  <jats:p>Preeclampsia (PE) and intrauterine growth restriction (IUGR) are separate disease entities that have frequently been reported as sharing the same pathogenesis. In both of them, angiogenesis disorders and generalized endothelial damage with an accompanying inflammation are the dominant symptoms. In this study, we attempted to prove that both these processes demonstrate the same profile in early PE, late PE and IUGR patients, while the only difference is in the degree of exacerbation of the lesions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpm-2016-0178_s_998_w2aab3b7b3b1b6b1aab1c17b2Aa\">\n                  <jats:title id=\"d1389240e6939_w2aab3b7b3b1b6b1aab1c17b2aAa\">Patients, materials and methods:<\/jats:title>\n                  <jats:p>In 167 patients divided into four groups, three of those with early PE, late PE and IUGR and one control group, fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF), high sensitive c-reactive protein (hsCRP) and fibronectin were determined. The behavior of these parameters in each of the groups was studied, and correlations between them were sought for.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpm-2016-0178_s_997_w2aab3b7b3b1b6b1aab1c17b3Aa\">\n                  <jats:title id=\"d1389240e6947_w2aab3b7b3b1b6b1aab1c17b3aAa\">Results:<\/jats:title>\n                  <jats:p>Higher concentrations of sFlt-1, hsCRP and fibronectin and a lower concentration of PlGF were found in the study groups compared to the control group. Significant correlations were observed between the factors concerned.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpm-2016-0178_s_996_w2aab3b7b3b1b6b1aab1c17b4Aa\">\n                  <jats:title id=\"d1389240e6955_w2aab3b7b3b1b6b1aab1c17b4aAa\">Conclusions:<\/jats:title>\n                  <jats:p>The higher values of disordered angiogenesis markers, endothelial damage markers and inflammatory markers both in the PE and the intrauterine growth restriction (IUGR) groups suggest the existence of shared disorders in the development of these pathologies. The correlations between disordered angiogenesis markers and endothelial damage markers argue in favor of a mutual relationship between these two processes in the development of pathologies evolving as secondary to placental ischemia. The results obtained confirm that the lesion profiles are the same in both PE and IUGR patients, which can be utilized in developing common diagnostic criteria.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpm-2016-0178","type":"journal-article","created":{"date-parts":[[2016,11,19]],"date-time":"2016-11-19T10:02:10Z","timestamp":1479549730000},"page":"793-802","source":"Crossref","is-referenced-by-count":20,"title":["Maternal endothelial damage as a disorder shared by early preeclampsia, late preeclampsia and intrauterine growth restriction"],"prefix":"10.1515","volume":"45","author":[{"given":"Sebastian","family":"Kwiatkowski","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology , Pomeranian Medical University, 2 Teaching Hospital , 70-111 Szczecin, Powstancow Wielkopolskich 72 , Szczecin , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Do\u0142egowska","sequence":"additional","affiliation":[{"name":"Laboratory Medicine Department , Pomeranian Medical University , Szczecin , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Kwiatkowska","sequence":"additional","affiliation":[{"name":"Department of Nephrology Transplantology and Internal Medicine , Pomeranian Medical University , Szczecin , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"Rzepka","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology , Pomeranian Medical University , Szczecin , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Marczuk","sequence":"additional","affiliation":[{"name":"Laboratory Medicine Department , Pomeranian Medical University , Szczecin , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Loj","sequence":"additional","affiliation":[{"name":"Universitatklinikum Greifswald, Department of Obstetrics and Gynecology , Mecklenburg- Vorpommern , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Torb\u00e8","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology , Pomeranian Medical University , Szczecin , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2016,11,19]]},"reference":[{"key":"2023040100153353595_j_jpm-2016-0178_ref_001_w2aab3b7b3b1b6b1ab1b6b1Aa","unstructured":"Brosens IA, Robertson WB, Dixon HG. The role of spiral arteries in the pathogenesis of preeclampsia. Obset Gynecol Annu. 1972;1:177\u201391."},{"key":"2023040100153353595_j_jpm-2016-0178_ref_002_w2aab3b7b3b1b6b1ab1b6b2Aa","doi-asserted-by":"crossref","unstructured":"Ghosh SK, Raheja S, Tuli A, Raghunandan C, Agarwal S. Is serum placental growth factor more effective as a biomarker in predicting early onset preeclampsia in early second trimester than in first trimester of pregnancy? Arch Gynecol Obstet. 2013;287:865\u201373.2322469910.1007\/s00404-012-2662-2","DOI":"10.1007\/s00404-012-2662-2"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_003_w2aab3b7b3b1b6b1ab1b6b3Aa","doi-asserted-by":"crossref","unstructured":"Chaiworapongsa T, Romero R, Korzeniewski SJ, Kusanovic JP, Soto E, Lam J, et al. Maternal plasma concentrations of angiogenic\/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol. 2013;208:287.e1-287-15.","DOI":"10.1016\/j.ajog.2013.01.016"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_004_w2aab3b7b3b1b6b1ab1b6b4Aa","doi-asserted-by":"crossref","unstructured":"Lehnen H, Mosblech N, Reineke T, Puchooa A, Menke-M\u00f6llers I, et al. Prenatal clinical assessment of sFlt-1 (Soluble fms-like Tyrosine Kinase-1)\/PlGF (placental growth factor) ratio as a diagnostic tool for preeclampsia, pregnancy-induced hypertension, and Proteinuria. Geburtshilfe Frauenheilkd. 2013;73:440\u20135.10.1055\/s-0032-132860124771924","DOI":"10.1055\/s-0032-1328601"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_005_w2aab3b7b3b1b6b1ab1b6b5Aa","doi-asserted-by":"crossref","unstructured":"Ghosh SK, Raheja S, Tuli A, Raghunandan C, Agarwal S. Can maternal serum placental growth factor estimation in early second trimester predict the occurrence of early onset preeclampsia and\/or early onset intrauterine growth restriction? A prospective cohort study. Obstet Gynaecol Res. 2013;39: 881\u201390.10.1111\/jog.12006","DOI":"10.1111\/jog.12006"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_006_w2aab3b7b3b1b6b1ab1b6b6Aa","doi-asserted-by":"crossref","unstructured":"Gerretsen GG, Huisjes HJ, Elema JD. Morphological changes of the spiral arteries in the placental bed in relation to pre-eclampsia and fetal growth retardation. Br J Obstet Gynaecol. 1981;88:876\u201381.10.1111\/j.1471-0528.1981.tb02222.x7272259","DOI":"10.1111\/j.1471-0528.1981.tb02222.x"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_007_w2aab3b7b3b1b6b1ab1b6b7Aa","doi-asserted-by":"crossref","unstructured":"Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol. 1986;93:1049\u201359.379046410.1111\/j.1471-0528.1986.tb07830.x","DOI":"10.1111\/j.1471-0528.1986.tb07830.x"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_008_w2aab3b7b3b1b6b1ab1b6b8Aa","doi-asserted-by":"crossref","unstructured":"Cindrova-Davies T, Herrera EA, Niu Y, Kindom J, Giussani DA, Burton GJ. Reduced cystathionine y-lyase and increased miR-21expression are associated with increased vascular resistance in growth-restricted pregnancies: hydrogen sulfide as a placental vasodilator. Am J Pathol. 2013;182:1448\u201358.10.1016\/j.ajpath.2013.01.001","DOI":"10.1016\/j.ajpath.2013.01.001"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_009_w2aab3b7b3b1b6b1ab1b6b9Aa","doi-asserted-by":"crossref","unstructured":"Labarrere C, Althabe O. Chronic villitis of unknown etiology and maternal arterial lesions in preeclamptic pregnancies. Eur J Obstet Gynecol Reprod Biol. 1985;20:1\u201311.10.1016\/0028-2243(85)90077-24029472","DOI":"10.1016\/0028-2243(85)90077-2"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_010_w2aab3b7b3b1b6b1ab1b6c10Aa","doi-asserted-by":"crossref","unstructured":"Pathak S, Lees CC, Hackett G, Jessop F, Sebire NJ. Frequency and clinical significance of placental histological lesions in an unselected population at or near term. Virchows Arch. 2011;459:565\u201372.10.1007\/s00428-011-1157-z","DOI":"10.1007\/s00428-011-1157-z"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_011_w2aab3b7b3b1b6b1ab1b6c11Aa","doi-asserted-by":"crossref","unstructured":"Salafia CM, Minior VK, Pezzullo JC, Popek EJ, Rosenkranz TS, Vintzileos AM. Intrauterine growth restriction in infants of less than thirty-two weeks gestation; associated placental pathologic features. Am J Obstet Gynecol. 1995;173:1049\u201357.748529210.1016\/0002-9378(95)91325-4","DOI":"10.1016\/0002-9378(95)91325-4"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_012_w2aab3b7b3b1b6b1ab1b6c12Aa","doi-asserted-by":"crossref","unstructured":"Slafia CM, Pezzullo JC, Lopez-Zeno JA, Simmenes S, Minior VK, Vintzileos AM. Placental pathologic features of preterm preeclampsia. Am J Obstet Gynecol. 1995;173:1097\u2013105.748530010.1016\/0002-9378(95)91333-5","DOI":"10.1016\/0002-9378(95)91333-5"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_013_w2aab3b7b3b1b6b1ab1b6c13Aa","doi-asserted-by":"crossref","unstructured":"Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785\u201399.1573372110.1016\/S0140-6736(05)71003-5","DOI":"10.1016\/S0140-6736(05)71003-5"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_014_w2aab3b7b3b1b6b1ab1b6c14Aa","doi-asserted-by":"crossref","unstructured":"Ness RB, Sibai BM. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol. 2006;195:40\u20139.10.1016\/j.ajog.2005.07.04916813742","DOI":"10.1016\/j.ajog.2005.07.049"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_015_w2aab3b7b3b1b6b1ab1b6c15Aa","doi-asserted-by":"crossref","unstructured":"Crispi F, Dominguez C, Llurba E, Martin-Gallan P, Cabero L, Gratacos E. Placental angiogenic growth factor and uterine artery Doppler findings for characterization, of different subset in preeclampsia and in isolated intrauterine growth restriction. Am J Obset Gynecol. 2006;195:201\u20137.10.1016\/j.ajog.2006.01.014","DOI":"10.1016\/j.ajog.2006.01.014"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_016_w2aab3b7b3b1b6b1ab1b6c16Aa","doi-asserted-by":"crossref","unstructured":"Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res. 2004;95:884\u201391.10.1161\/01.RES.0000147365.86159.f515472115","DOI":"10.1161\/01.RES.0000147365.86159.f5"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_017_w2aab3b7b3b1b6b1ab1b6c17Aa","doi-asserted-by":"crossref","unstructured":"Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt-1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649\u201358.10.1172\/JCI17189","DOI":"10.1172\/JCI17189"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_018_w2aab3b7b3b1b6b1ab1b6c18Aa","doi-asserted-by":"crossref","unstructured":"Wallner W, Sengerberger R, Strick R, Strissel PL, Meurer B, Beckmann MW, et al. Angiogenic growth factor in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci. (lond) 2007;112:51\u20137.10.1042\/CS2006016116928195","DOI":"10.1042\/CS20060161"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_019_w2aab3b7b3b1b6b1ab1b6c19Aa","doi-asserted-by":"crossref","unstructured":"Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992\u20131005.1695714610.1056\/NEJMoa055352","DOI":"10.1056\/NEJMoa055352"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_020_w2aab3b7b3b1b6b1ab1b6c20Aa","doi-asserted-by":"crossref","unstructured":"Jacobs M, Nassar N, Roberts CL, Hadfield R, Morris JM, Ashton AW. Levels of soluble fms-like tyrosine kinase one in first trimester and outcomes of pregnancy: a systematic review. Reprod Biol Endocrinol. 2011;9:77.2164993810.1186\/1477-7827-9-77","DOI":"10.1186\/1477-7827-9-77"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_021_w2aab3b7b3b1b6b1ab1b6c21Aa","doi-asserted-by":"crossref","unstructured":"Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med. 2009;22:1021\u201338.10.3109\/1476705090299475419900040","DOI":"10.1080\/14767050902994754"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_022_w2aab3b7b3b1b6b1ab1b6c22Aa","doi-asserted-by":"crossref","unstructured":"Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012;125:911\u201319.10.1161\/CIRCULATIONAHA.111.05436122261192","DOI":"10.1161\/CIRCULATIONAHA.111.054361"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_023_w2aab3b7b3b1b6b1ab1b6c23Aa","doi-asserted-by":"crossref","unstructured":"Bakalis S, Gallo DM, Mendez O, et al. Prediction of small-forgestational-age neonates: screening by maternal biochemical markers at 30\u201334 weeks. Ultrasound Obstet Gynecol. 2015;46:208\u201315.2582679710.1002\/uog.14861","DOI":"10.1002\/uog.14861"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_024_w2aab3b7b3b1b6b1ab1b6c24Aa","doi-asserted-by":"crossref","unstructured":"Herraiz I, Droge LA, Gomez-Montes E, Poon LC, Nicolaides KH. Characterization of the soluble fms-like tyrosine kinase-1 to placental growth factor ratio in pregnancies complicated by fetal growth restriction. Obstet Gynecol. 2014;124:265\u201373.10.1097\/AOG.000000000000036725004342","DOI":"10.1097\/AOG.0000000000000367"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_025_w2aab3b7b3b1b6b1ab1b6c25Aa","doi-asserted-by":"crossref","unstructured":"Alahakoon TI, Zhang W, Trudinger BJ, Lee VW. Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro- and anti-angiogenic profiles. J Matern Fetal Neonatal Med. 2014;27:1854\u20139.2439748310.3109\/14767058.2014.880882","DOI":"10.3109\/14767058.2014.880882"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_026_w2aab3b7b3b1b6b1ab1b6c26Aa","doi-asserted-by":"crossref","unstructured":"Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669\u201376.10.1038\/nm0603-66912778165","DOI":"10.1038\/nm0603-669"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_027_w2aab3b7b3b1b6b1ab1b6c27Aa","doi-asserted-by":"crossref","unstructured":"Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA. 1993;90:10705\u20139.10.1073\/pnas.90.22.10705","DOI":"10.1073\/pnas.90.22.10705"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_028_w2aab3b7b3b1b6b1ab1b6c28Aa","doi-asserted-by":"crossref","unstructured":"Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, et al. Auticrine VEGF signaling is required for vascular homeostasis. Cell. 2007;130:691\u2013703.10.1016\/j.cell.2007.06.05417719546","DOI":"10.1016\/j.cell.2007.06.054"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_029_w2aab3b7b3b1b6b1ab1b6c29Aa","doi-asserted-by":"crossref","unstructured":"Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308:1592\u20134.10.1126\/science.111172615947178","DOI":"10.1126\/science.1111726"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_030_w2aab3b7b3b1b6b1ab1b6c30Aa","doi-asserted-by":"crossref","unstructured":"Roberts JM. Objective evidence of endothelial dysfunction in preeclampsia. Am J Kidney Dis. 1999;33:992\u20137.10.1016\/S0272-6386(99)70439-710328745","DOI":"10.1016\/S0272-6386(99)70439-7"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_031_w2aab3b7b3b1b6b1ab1b6c31Aa","doi-asserted-by":"crossref","unstructured":"Roberts JM. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol. 1998;16:5\u201315.965460310.1055\/s-2007-1016248","DOI":"10.1055\/s-2007-1016248"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_032_w2aab3b7b3b1b6b1ab1b6c32Aa","doi-asserted-by":"crossref","unstructured":"Roberts JM. Preeclampsia: not simply pregnancy-induced hypertension. Hosp Pract. 1995;3028:31\u20136.","DOI":"10.1080\/21548331.1995.11443299"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_033_w2aab3b7b3b1b6b1ab1b6c33Aa","doi-asserted-by":"crossref","unstructured":"Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol. 1989;161:1200\u20134.10.1016\/0002-9378(89)90665-02589440","DOI":"10.1016\/0002-9378(89)90665-0"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_034_w2aab3b7b3b1b6b1ab1b6c34Aa","doi-asserted-by":"crossref","unstructured":"Fredman SA, Lubarsky SL, Ahokas RA, Nova A, Sibai BM. Preeclampsia and related disorders. Clinical aspects and relevance of endothelin and nitric oxide. Clin Perinatol. 1995;22:343\u201355.7671541","DOI":"10.1016\/S0095-5108(18)30287-2"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_035_w2aab3b7b3b1b6b1ab1b6c35Aa","doi-asserted-by":"crossref","unstructured":"Morris NH, Eaton BM, Dekker G. Nitric oxide the endothelium, pregnancy and pre-eclampsia. Br J Obstet Gynaecol. 1996;103:4\u201315.10.1111\/j.1471-0528.1996.tb09508.x8608097","DOI":"10.1111\/j.1471-0528.1996.tb09508.x"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_036_w2aab3b7b3b1b6b1ab1b6c36Aa","doi-asserted-by":"crossref","unstructured":"Roberts JM, Taylor RN, Golgfien A. Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am J Hypertens. 1991;4:700\u20138.193085310.1093\/ajh\/4.8.700","DOI":"10.1093\/ajh\/4.8.700"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_037_w2aab3b7b3b1b6b1ab1b6c37Aa","doi-asserted-by":"crossref","unstructured":"Clark R, Quin HJ, Winn JM, Lanigan PD, Colvin RB. Fibronectin is produced by blood vessels in response to injury. J Exp Med. 1982;156:646\u201351.704767210.1084\/jem.156.2.646","DOI":"10.1084\/jem.156.2.646"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_038_w2aab3b7b3b1b6b1ab1b6c38Aa","doi-asserted-by":"crossref","unstructured":"Dane C, Buyukasik H, Dane B, Yayla M. Maternal plasma fibronectin and advanced oxidative protein product for the prediction of preeclampsia in high risk pregnancies: a prospective cohort study. Fetal Diagn Ther. 2009;26:189\u201394.10.1159\/000259317","DOI":"10.1159\/000259317"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_039_w2aab3b7b3b1b6b1ab1b6c39Aa","doi-asserted-by":"crossref","unstructured":"Biskupska Bodovaa K, Biringera K, Dokusa K, Ivankovab J, Staskob J, Dankoa J. Fibronectin, plasminogen activator inhibitor type 1 (PAI-1) and uterine artery Doppler velocimetry as markers of preeclampsia. Dis Markers. 2011;30:191\u20136.2169444510.1155\/2011\/219350","DOI":"10.1155\/2011\/219350"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_040_w2aab3b7b3b1b6b1ab1b6c40Aa","doi-asserted-by":"crossref","unstructured":"Friedman SA, de Groot CJ, Taylor RN, Golditch BD, Roberts JM. Plasma cellular fibronectin as a measure of endothelial involvement in preeclampsia and intrauterine growth retardation. Am J Obstet Gynecol. 1994;170:838\u201341.10.1016\/S0002-9378(94)70295-08141213","DOI":"10.1016\/S0002-9378(94)70295-0"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_041_w2aab3b7b3b1b6b1ab1b6c41Aa","doi-asserted-by":"crossref","unstructured":"Tjoa ML, Oudejans CB, Vugt JM. Markers for Presymptomatic Prediction of Preeclampsia and Intrauterine Growth Restriction. Hypertens Pregnancy. 23:171\u201389.","DOI":"10.1081\/PRG-120028292"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_042_w2aab3b7b3b1b6b1ab1b6c42Aa","doi-asserted-by":"crossref","unstructured":"Powers RW, Catov JM, Bodnar LM, Gallaher MJ, Lain BSKY, Roberts JM. Evidence of endothelial dysfunction in preeclampsia and risk of adverse pregnancy outcome. Reprod Sci. 2008;15:374\u201381.1818740610.1177\/1933719107311780","DOI":"10.1177\/1933719107311780"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_043_w2aab3b7b3b1b6b1ab1b6c43Aa","doi-asserted-by":"crossref","unstructured":"Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 2008;21:9\u201323.18175241","DOI":"10.1080\/14767050701830480"},{"key":"2023040100153353595_j_jpm-2016-0178_ref_044_w2aab3b7b3b1b6b1ab1b6c44Aa","doi-asserted-by":"crossref","unstructured":"Conrad KP, Miles TM, Benyo DF. Circulating levels of immunorective cytokines in women with preeclampsia. Am J Reprod Immunol. 1998;40:102\u201311.10.1111\/j.1600-0897.1998.tb00398.x","DOI":"10.1111\/j.1600-0897.1998.tb00398.x"}],"container-title":["Journal of Perinatal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/jpme.2017.45.issue-7\/jpm-2016-0178\/jpm-2016-0178.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2016-0178\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2016-0178\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T14:31:24Z","timestamp":1680359484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2016-0178\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,19]]},"references-count":44,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,4,13]]},"published-print":{"date-parts":[[2017,10,26]]}},"alternative-id":["10.1515\/jpm-2016-0178"],"URL":"https:\/\/doi.org\/10.1515\/jpm-2016-0178","relation":{},"ISSN":["1619-3997","0300-5577"],"issn-type":[{"value":"1619-3997","type":"electronic"},{"value":"0300-5577","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11,19]]}}}